Suppr超能文献

大鼠体内肿瘤与来自甲基丁香酚和他莫昔芬的DNA加合物的相关性。

Correlation of tumors with DNA adducts from methyl eugenol and tamoxifen in rats.

作者信息

Waddell William J, Crooks Neil H, Carmichael Paul L

机构信息

Department of Pharmacology and Toxicology, School of Medicine, University of Louisville, Louisville, Kentucky, USA.

出版信息

Toxicol Sci. 2004 May;79(1):38-40. doi: 10.1093/toxsci/kfh088. Epub 2004 Feb 19.

Abstract

Data on percent tumors in male rats after administration of methyl eugenol, obtained from the National Toxicology Program, or tamoxifen were plotted on a linear scale for percent tumors against the dose on a logarithmic scale. Data on (32)P-postlabelled DNA adducts were plotted on the same graphs for each of these two compounds in order to correlate adduct formation and tumor incidence with dose. The resulting graph for methyl eugenol showed a linear response for both adduct formation and tumor incidence. The threshold dose of administered methyl eugenol for adduct formation (zero adducts) was 10(19.3) molecules of methyl eugenol/kg/day, which compared with a threshold of 10(20.1) molecules of methyl eugenol/kg/day for tumor formation; however, 30 adducts/10(8) nucleotides was the threshold for tumor formation. The dose of tamoxifen for adduct formation fit an exponential plot slightly better than a linear plot, but reached minimal values close to the threshold of 10(18.7) molecules of tamoxifen/kg/day for tumor formation. These data confirm that tumor formation coincides with adduct formation and that both have thresholds, or at least reach minimal values, above levels to which humans are exposed. Although the threshold dose for tumor formation from tamoxifen is only about 10x above the dose received by women at risk for breast cancer, this should be an adequate safety margin. The safety factor for methyl eugenol is several orders of magnitude; therefore, there should be no cause for concern for humans at current levels of exposure.

摘要

从美国国家毒理学计划获取的雄性大鼠在给予甲基丁香酚或他莫昔芬后肿瘤百分比的数据,以肿瘤百分比的线性比例对应对数比例的剂量绘制。针对这两种化合物中的每一种,将(32)P后标记的DNA加合物数据绘制在同一张图表上,以便将加合物形成和肿瘤发生率与剂量相关联。甲基丁香酚的最终图表显示加合物形成和肿瘤发生率均呈线性反应。甲基丁香酚给药后加合物形成的阈剂量(零加合物)为10(19.3)个甲基丁香酚分子/千克/天,与之相比,肿瘤形成的阈剂量为10(20.1)个甲基丁香酚分子/千克/天;然而,每10(8)个核苷酸30个加合物是肿瘤形成的阈值。他莫昔芬加合物形成的剂量拟合指数图略优于线性图,但在接近肿瘤形成阈剂量10(18.7)个他莫昔芬分子/千克/天处达到最小值。这些数据证实肿瘤形成与加合物形成一致,且两者都有阈值,或至少在人类暴露水平以上达到最小值。尽管他莫昔芬导致肿瘤形成的阈剂量仅比有乳腺癌风险的女性所接受的剂量高约10倍,但这应该是一个足够的安全边际。甲基丁香酚的安全系数有几个数量级;因此,在当前暴露水平下,对人类来说应该没有担忧的理由。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验